With applied Genomics expertise, global co-location with Central Labs and solutions from biomarker discovery to CDx, our genomics solutions will help make your Precision Medicine drug development a reality.

1. Genomics Solutions
Single Target to Whole Genome Analysis
With applied genomics expertise, transformative investments, global co-location with the #1
Central Labs provider and unmatched solutions from biomarker discovery to CDx, we’ll help
you make your Precision Medicine a reality, faster.
Applied genomics expertise
from single target to whole genome analysis for exploratory
and regulated testing across a broad range of platforms
Transformative investments
globally deliver scale, scope and innovation today and in the future
Global co-location with the #1 Provider
of Central Labs, logistics and specimen management services
Unmatched solutions from biomarker discovery
to CDx via personalized biomarker support to help drive your
development from bench to commercialization
Comprehensive Applications:
Gene Expression
Multiple tools for PD biomarkers
▶ Whole genome - microarray or NGS
▶ Targeted panels - RT-qPCR, nanoString, NGS
miRNA
Novel biomarkers for disease monitoring
▶ Whole genome - microarray, RT-qPCR, NGS
▶ Targeted panels - Exiqon or TaqMan
Genotyping
Predictive biomarkers
▶ Detailed genome or exome analysis
▶ Targeted panels - qPCR and ddPCR
Methylation
Multiple approaches for Epigenetics
▶ High-level surveys reveal patterns
▶ High-resolution analysis defines important regions
PGx
Known and Novel ADME markers
▶ Multiplexed panels - microarray, NGS
▶ Targeted panels - qPCR/OpenArray, microarray
Mutational Testing
Tumor Classification
▶ Pathway focused panels
▶ Targeted mutations - KRAS, BRAF, TP53, etc.
CNV
Reveal Dosage Imbalances
▶ Whole genome - microarray
▶ Targeted panels - qPCR, ddPCR, nanoString
BioBanking
Confidence in Sample Stability
▶ Sample characterization
▶ Multiple location options

2. Scientific Areas of Focus
Liquid Biopsies
▶ NGS analysis of CTCs and cfDNA
Immuno-Oncology
▶ Gene expression for autoimmune diseases
▶ Complementary approaches for immune
function profiling
Tumor Mutational Burden
▶ Whole exome sequencing
▶ Focused cancer gene panels
Microbiome
▶ 16S sequencing
▶ Whole genome sequencing
Innovations Advancing Precision Medicine Through
Cutting-Edge Science
Single-Cell Genomics Analysis
Resolve the complexities of disease biology
heterogeneity
Immune Profile Elucidation
Improved predictive performance for I/O therapies
Non-Invasive Biomarkers in
NASH
Applications of genotyping in drug development
Novel Assays
To advance therapies for rare and orphan diseases
Transformative Investments and Enhancements
Indianapolis Shanghai
Geneva Singapore
▶ New, 16K ft2
flagship lab
co-located with Central Labs
▶ Consolidates exploratory studies
and biomarker development,
patient management (CAP/CLIA)
laboratory testing and
CDx development
▶ New, state-of-the-art Aland
Center facility
▶ Genomics, Central Labs, APH,
Microbiology Immunology
▶ ~90% increase in genomics
laboratory footprint
▶ Diversified testing
▶ Next-generation sequencing
(NGS) platforms installation
▶ Expected completion in
early 2020
The Central Laboratory, Redefined Exploratory Biomarkers to CDx
▶ Whole genome analysis, onsite
▶ Translational biomarker solutions
▶ Advanced specialty testing capabilities
▶ Access to LabCorp Specialty Testing
Group labs
▶ Assay development and transfer
▶ Clinical trial assays under
Design Control
▶ Verification and Validation
▶ Regulatory support and
commercialization
Learn more about our drug development solutions at www.covance.com
Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research
services to the drug, medical device and diagnostic, crop protection and chemical industries. COVANCE is a
registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world.
www.covance.com
© Copyright 2020 Covance Inc. SSGENO001-0220